达帕格列嗪
医学
射血分数
安慰剂
内科学
心脏病学
置信区间
临床终点
利钠肽
生物标志物
临床试验
心功能曲线
舒张期
随机对照试验
脑利钠肽
二羟基化合物
麻醉
不利影响
心肌梗塞
作者
Hakar Abdulkareem Saeed,Nidhal A. K. Mohammed Ali,Ramadhan T. Othman
出处
期刊:Future Science OA
[Future Science Ltd]
日期:2026-10-06
卷期号:12 (1): 2741250-2741250
标识
DOI:10.1080/20565623.2026.2741250
摘要
Aims To evaluate whether dapagliflozin attenuates early cardiac functional and biomarker changes during anthracycline-based chemotherapy.Materials & Methods In this randomized, double-blind, placebo-controlled phase II trial, 94 adults were assigned 1:1 to dapagliflozin 10 mg once daily or placebo for 4 months; 90 completed follow-up. The primary endpoint was 4-month left ventricular ejection fraction (LVEF), analyzed using analysis of covariance (ANCOVA) adjusted for baseline LVEF. Secondary and exploratory outcomes included cardiac biomarkers and the early-to-late transmitral flow velocity ratio (E/A ratio).Results Dapagliflozin was associated with higher adjusted 4-month LVEF than placebo (adjusted mean difference, 2.40 percentage points; 95% confidence interval [CI], 1.25–3.54; p < 0.001). Change in LVEF was +0.13 ± 2.28 versus −2.31 ± 3.27 percentage points, respectively. E/A ratio decline was attenuated (p = 0.030). Galectin-3 decreased with dapagliflozin but increased with placebo (p < 0.001), while N-terminal pro-B-type natriuretic peptide (NT-proBNP) increased less (p = 0.004). No major safety signal was observed during the 4-month follow-up.Conclusions Dapagliflozin was associated with attenuation of early anthracycline-associated cardiac functional and biomarker changes. Larger, longer trials are needed to determine clinical benefit.Clinical trial registration www.clinicaltrials.gov identifier is NCT06888505. Retrospectively registered.
科研通智能强力驱动
Strongly Powered by AbleSci AI